Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.4.2.8 - hypoxanthine phosphoribosyltransferase and Organism(s) Homo sapiens and UniProt Accession P00492

for references in articles please use BRENDA:EC2.4.2.8
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     2 Transferases
         2.4 Glycosyltransferases
             2.4.2 Pentosyltransferases
                2.4.2.8 hypoxanthine phosphoribosyltransferase
IUBMB Comments
Guanine and purine-6-thiol can replace hypoxanthine.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
UNIPROT: P00492
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Synonyms
hprt, hgprt, hypoxanthine-guanine phosphoribosyltransferase, hprt1, hypoxanthine phosphoribosyltransferase, hypoxanthine-guanine phosphoribosyl transferase, hypoxanthine phosphoribosyl transferase, hypoxanthine guanine phosphoribosyltransferase, hgprtase, guanine phosphoribosyltransferase, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hypoxanthine guanine phosphoribosyltransferase
-
hypoxanthine phosphoribosyltransferase 1
-
hypoxanthine-guanine phosphoribosyl transferase
-
hypoxanthine-guanine phosphoribosyltransferase
-
hypoxanthine-guanine-xanthine phosphoribosyltransferase
-
plasma hypoxanthine-guanine phosphoribosyl transferase
-
6-hydroxypurine phosphoribosyltransferase
-
-
-
-
6-mercaptopurine phosphoribosyltransferase
-
-
-
-
GMP pyrophosphorylase
-
-
-
-
guanine phosphoribosyltransferase
-
-
-
-
guanine-hypoxanthine phosphoribosyltransferase
-
-
-
-
guanosine 5'-phosphate pyrophosphorylase
-
-
-
-
guanosine phosphoribosyltransferase
-
-
-
-
guanylate pyrophosphorylase
-
-
-
-
guanylic pyrophosphorylase
-
-
-
-
HGPRT
HGPRTase
-
-
-
-
HGXPRT
-
-
HPRTJerusalem
-
-
hypoxanthine guanine phosphoribosyltransferase
-
-
hypoxanthine-guanine phosphoribosyl transferase
-
-
hypoxanthine-guanine phosphoribosyltransferase
hypoxanthine-guanine-xanthine phosphoribosyltransferase
-
-
IMP pyrophosphorylase
-
-
-
-
IMP-GMP pyrophosphorylase
-
-
-
-
inosinate pyrophosphorylase
-
-
-
-
inosine 5'-phosphate pyrophosphorylase
-
-
-
-
inosinic acid pyrophosphorylase
-
-
-
-
inosinic pyrophosphorylase
-
-
-
-
phosphoribosyltransferase, 6-mercaptopurine
-
-
-
-
phosphoribosyltransferase, hypoxanthine
-
-
-
-
purine-6-thiol phosphoribosyltransferase
-
-
-
-
transphosphoribosidase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
IMP + diphosphate = hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
IMP + diphosphate = hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
pentosyl group transfer
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
IMP:diphosphate phospho-D-ribosyltransferase
Guanine and purine-6-thiol can replace hypoxanthine.
CAS REGISTRY NUMBER
COMMENTARY hide
9016-12-0
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
3-hydroxy-2-pyrazinecarboxamide + 5-phospho-alpha-D-ribose 1-diphosphate
3-oxo-4-(5-O-phosphono-beta-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide + diphosphate
show the reaction diagram
T-1105, poor substrate
-
-
?
3-hydroxy-2-pyrazinecarboxamide + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
T-1105, poor substrate
-
-
?
6-fluoro-3-hydroxy-2-pyrazinecarboxamide + 5-phospho-alpha-D-ribose 1-diphosphate
6-fluoro-3-oxo-4-(5-O-phosphono-beta-D-ribofuranosyl)-3,4-dihydropyrazine-2-carboxamide + diphosphate
show the reaction diagram
T-705, poor substrate
-
-
?
6-fluoro-3-hydroxy-2-pyrazinecarboxamide + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
T-705, poor substrate
-
-
?
GMP + diphosphate
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
?
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
guanosine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
IMP + diphosphate
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
?
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
xanthosine 5'-phosphate + diphosphate
show the reaction diagram
mutant F36L, no activity with the wild-type enzyme
-
-
?
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
wild-type human enzyme does not accept xanthine as substrate, mutant F36L does catalyze the conversion of xanthine to XMP with a kcat much lower than those of hypoxanthine and guanine
-
-
?
6-mercaptopurine + 5-phospho-alpha-D-ribose 1-diphosphate
6-thioinosine monophosphate + diphosphate
show the reaction diagram
-
-
-
-
?
6-mercaptopurine + 5-phospho-alpha-D-ribose 1-diphosphate
thioinosinic monophosphate + diphosphate
show the reaction diagram
-
a thiopurine antimetabolite
a therapeutically active metabolite
-
?
allopurinol + 5-phospho-alpha-D-ribose 1-diphosphate
allopurinol ribonucleoside 5'-monophosphate + diphosphate
show the reaction diagram
-
low activity
-
?
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
GMP + diphosphate
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
?
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
guanosine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
IMP + diphosphate
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
show the reaction diagram
-
-
-
?
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
? + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
xanthosine 5'-phosphate + diphosphate
show the reaction diagram
mutant F36L, no activity with the wild-type enzyme
-
-
?
guanine + 5-phospho-alpha-D-ribose 1-diphosphate
GMP + diphosphate
show the reaction diagram
hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate
IMP + diphosphate
show the reaction diagram
xanthine + 5-phospho-alpha-D-ribose 1-diphosphate
XMP + diphosphate
show the reaction diagram
-
-
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1S)-1-(9-deazaguanin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate
-
(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol 5-phosphate
-
(2-[(3R,4R)-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-4-[(2R)-2-hydroxy-2-phosphonoethoxy]pyrrolidin-1-yl]-2-oxoethyl)phosphonic acid
enzyme-bound crystal structure analysis
(2-[3-(8-bromoguanin-9-yl)-2-(2-(bishydroxyphosphoryl)-ethoxy)propoxy]ethyl)phosphonic acid
-
(2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl)phosphonic acid
-
(R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-8-bromoguanine
-
(R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
is toxic to cells and arrests cell growth
(S)-3-(guanin-9-yl)-pyrrolidin-N-ylacetylphosphonic acid
-
(S)-9-[2-(phosphonomethoxy)propyl]guanine
-
(S)-9-[2-(phosphonomethoxy)propyl]hypoxanthine
-
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-8-azaguanine
-
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]-8-bromoguanine
-
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
([2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid
-
([2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-3-(2-phosphonoethoxy)propoxy]methyl)phosphonic acid
-
([3-(7-deazaguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(7-deazahypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(8-bromoguanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(8-bromohypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid
sodium salt
([3-(hypoxanthine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methyl)phosphonic acid
sodium salt
6-methylheptyl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
-
9-[2-(2-phosphonoethoxy)ethyl]guanine
-
9-[2-(2-phosphonoethoxy)ethyl]hypoxanthine
-
9-[2-(phosphonomethoxy)-3-fluoro-propyl]guanine
-
9-[2-(phosphonomethoxy)ethyl]-6-thioguanine
-
9-[2-(phosphonomethoxy)ethyl]-7-deaza-8-azahypoxanthine
-
9-[2-(phosphonomethoxy)ethyl]-8-azaguanine
-
9-[2-(phosphonomethoxy)ethyl]-8-bromoguanine
-
9-[2-(phosphonomethoxy)ethyl]guanine
9-[2-(phosphonomethoxy)ethy]-8-hydroxyguanine
-
acyclic nucleoside phosphonates
analogues of the nucleotide reaction product, comprising a purine base joined by a linker to a phosphonate moiety, inhibitor design and potencies, overview. The inhibitors are selectivity for the enzyme of the human parasite Plasmodium falciparum, up to factor 58, compared to the human enzyme, overview
cyclic (R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
is toxic to cells and arrests cell growth
cyclic (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
is toxic to cells and arrests cell growth
diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-2,15-dibenzyl-8-[(8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-8-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
-
diethyl (2S,15S)-8-[(2-amino-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
diethyl (2S,15S)-8-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-4,13-bis[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]-4,13-dioxo-2,15-bis(2-phenylethyl)-6,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
-
diethyl (2S,15S)-8-[(2-amino-8-bromo-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]-2,15-dibenzyl-4,13-bis[[(2S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl]amino]-4,13-dioxo-7,10-dioxa-3,14-diaza-4lambda5,13lambda5-diphosphahexadecane-1,16-dioate
prodrug
guanine ribose 5'-phosphate
-
hypoxanthine ribose 5'-phosphate
-
immucillin-G 5'-phosphate
active site contacts in the HGPRT/immucillin-G 5'-phosphate/diphosphate complex, overview
immucillin-H 5'-phosphate
5'-phosphate binding structure on HGPRT, overview
propan-2-yl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
-
[(1S)-1-hydroxy-2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl]phosphonic acid
-
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid
structure bound in the active site of human HGPRT (PDB ID 4IJQ), molecular docking. The crystal structure shows that a magnesium ion is coordinated to one of the sulfate oxygen atoms and one of the phosphonate oxygen atoms of the inhibitor
[3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
-
[[2-[(6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]propane-1,3-diyl]bis(oxymethylene)]bis(phosphonic acid)
-
(3-hydroxy-2-[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]propyl)phosphonic acid
-
-
3-((7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methylamino)propylphosphonate
-
-
Hg2+
-
complete inhibition at 3 mM after 3 min at 0°C
KCl
-
no inhibition
Pb2+
-
inhibits the enzyme in erythrocytes about 20% at 0.0005 mM and about 12% at 0.0001 mM, and participates in hemolysis, the intensity of which negatively correlates with the activity of phosphoribosyltransferases, HPRT inhibition as one of the mechanisms of lead toxicity
[(+/-)-2(R/S)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
-
-
[(+/-)-2(R/S)-[([2-chloro-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
-
[(2R)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
-
[(2R)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
-
-
[(2S)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
-
[(2S,3R)-2,4-dihydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butoxy]phosphonic acid
-
-
[(3R)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
-
[(3S)-1,1-difluoro-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
-
[(3S)-3-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-1,1-difluoro-4-hydroxybutyl]phosphonic acid
-
-
[(3S)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
-
[2-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl] phosphonic acid
-
-
[2-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]ethyl]phosphonic acid
-
-
[2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethoxy]phosphonic acid
-
-
[3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-2-(hydroxymethyl)propoxy]phosphonic acid
-
-
[3-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]propyl]phosphonic acid
-
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethyl]phosphonic acid
-
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]phosphonic acid
-
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]pentyl]phosphonic acid
-
-
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl]phosphonic acid
-
-
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
4.069
3-hydroxy-2-pyrazinecarboxamide
at pH 7.4 and 37°C
0.001 - 1.075
5-phospho-alpha-D-ribose 1-diphosphate
6.426
6-fluoro-3-hydroxy-2-pyrazinecarboxamide
at pH 7.4 and 37°C
0.0011 - 0.0061
guanine
0.0014 - 0.0044
hypoxanthine
0.287 - 0.332
xanthine
0.0191 - 1.156
5-phospho-alpha-D-ribose 1-diphosphate
0.135
allopurinol
-
recombinant enzyme
0.0175 - 0.968
diphosphate
0.0011 - 0.134
guanine
0.001 - 0.126
hypoxanthine
0.0024 - 1.043
IMP
0.0054
inosine monophosphate
-
recombinant enzyme
0.3
xanthine
-
above, purified recombinant chimeric enzyme DS1
additional information
additional information
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.37 - 25.5
guanine
0.47 - 7.1
hypoxanthine
0.07 - 2.9
xanthine
2.5 - 20.3
5-phospho-alpha-D-ribose 1-diphosphate
0.041 - 0.33
diphosphate
0.013 - 10.5
guanine
0.073 - 20.3
hypoxanthine
0.038 - 0.51
IMP
0.23 - 0.3
inosine monophosphate
-
recombinant enzyme, reverse reaction
0.062
xanthine
-
purified recombinant chimeric enzyme DS1
additional information
additional information
-
kinetics
-
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.14
3-hydroxy-2-pyrazinecarboxamide
at pH 7.4 and 37°C
0.027
6-fluoro-3-hydroxy-2-pyrazinecarboxamide
at pH 7.4 and 37°C
140
guanine
at pH 7.4 and 37°C
130
hypoxanthine
at pH 7.4 and 37°C
0.004 - 0.1
5-phospho-alpha-D-ribose 1-diphosphate
0.0003 - 0.002
diphosphate
0.7 - 3.8
hypoxanthine
0.0024 - 1
IMP
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000008
(2-[(3R,4R)-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-4-[(2R)-2-hydroxy-2-phosphonoethoxy]pyrrolidin-1-yl]-2-oxoethyl)phosphonic acid
pH not specified in the publication, 37°C
0.041
(R)-9-[2-(phosphonomethoxy)propyl]-8-bromoguanine
pH 7.4, 25°C
0.0059
(R,S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
pH 7.4, 25°C
0.073
(S)-3-(guanin-9-yl)-pyrrolidin-N-ylacetylphosphonic acid
pH not specified in the publication, 37°C
0.015
(S)-9-[2-(phosphonomethoxy)propyl]-8-azaguanine
pH 7.4, 25°C
0.3
(S)-9-[2-(phosphonomethoxy)propyl]-8-bromoguanine
above, pH 7.4, 25°C
0.1823
(S)-9-[2-(phosphonomethoxy)propyl]hypoxanthine
pH 8.5, 25°C
0.1768
(S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
pH 8.5, 25°C
1
6-methylheptyl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
above, pH 7.4, 25°C
0.001
9-[2-(2-phosphonoethoxy)ethyl]guanine
pH 7.4, 25°C
0.0036
9-[2-(2-phosphonoethoxy)ethyl]hypoxanthine
pH 7.4, 25°C
0.0227
9-[2-(phosphonomethoxy)-3-fluoro-propyl]guanine
pH 8.5, 25°C
1
9-[2-(phosphonomethoxy)ethyl]-6-thioguanine
above, pH 7.4, 25°C
0.0043
9-[2-(phosphonomethoxy)ethyl]-7-deaza-8-azahypoxanthine
pH 7.4, 25°C
0.175
9-[2-(phosphonomethoxy)ethyl]-8-azaguanine
pH 7.4, 25°C
0.4
9-[2-(phosphonomethoxy)ethyl]-8-bromoguanine
above, pH 7.4, 25°C
0.029 - 0.0559
9-[2-(phosphonomethoxy)ethyl]guanine
0.068
9-[2-(phosphonomethoxy)ethy]-8-hydroxyguanine
pH 7.4, 25°C
0.0123 - 0.019
cyclic (R)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
0.09 - 0.1151
cyclic (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine
0.0058
guanine ribose 5'-phosphate
pH 7.4, 25°C
0.0054
hypoxanthine ribose 5'-phosphate
pH 7.4, 25°C
0.14
propan-2-yl hydrogen {[2-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)ethoxy]methyl}phosphonate
pH 7.4, 25°C
0.0000013
[(1S)-1-hydroxy-2-[[(3R,4R)-4-(6-oxo-1,6-dihydro-9H-purin-9-yl)-1-(phosphonoacetyl)pyrrolidin-3-yl]oxy]ethyl]phosphonic acid
pH not specified in the publication, 37°C
0.00007
[3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid
pH 7.4, temperature not specified in the publication
0.000003 - 0.00002
[3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine
0.01
(3-hydroxy-2-[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]propyl)phosphonic acid
-
at pH 7.6 and 37°C
0.01
3-((7-hydroxy-1H-pyrazolo[4,3-d]pyrimidin-3-yl)methylamino)propylphosphonate
-
at pH 7.6 and 37°C
0.01
[(+/-)-2(R/S)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[(+/-)-2(R/S)-[([2-chloro-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[(2R)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[(2R)-3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[(2S)-2-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-3-hydroxypropoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[(2S,3R)-2,4-dihydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.016 - 0.042
[(3R)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
0.01
[(3S)-1,1-difluoro-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[(3S)-3-[([2-amino-4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-1,1-difluoro-4-hydroxybutyl]phosphonic acid
-
at pH 7.6 and 37°C
0.00038
[(3S)-4-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[2-hydroxy-3-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl] phosphonic acid
-
at pH 7.6 and 37°C
0.01
[2-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]ethyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[3-hydroxy-2-[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]-2-(hydroxymethyl)propoxy]phosphonic acid
-
at pH 7.6 and 37°C
0.01132
[3-[(2-[4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]ethyl)amino]propyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]butyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]ethyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]methyl]phosphonic acid
-
at pH 7.6 and 37°C
0.01
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]pentyl]phosphonic acid
-
at pH 7.6 and 37°C
0.0049
[[([4-hydroxy-5H-pyrrolo[3,2-d]pyrimidin-7-yl]methyl)amino]propyl]phosphonic acid
-
at pH 7.6 and 37°C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00016
F199C mutant erythrocytes
0.0002 - 0.00029
wild-type erythrocytes
0.0021
enzyme activity in erythrocytes, pH 8.8, 25°C
0.0008
-
wild-type MN9D cells
0.032
-
purified recombinant chimeric enzyme DS1, substrate guanine
0.147
-
purified recombinant chimeric enzyme DS1, substrate xanthine
0.226
-
purified recombinant chimeric enzyme DS1, substrate hypoxanthine
0.27
-
purified recombinant enzyme, substrate allopurinol, pH 8.0
0.57 - 0.76
-
recombinant enzyme, reverse reaction
11.9
-
purified recombinant enzyme, substrate hypoxanthine
17.5
-
purified enzyme, erythrocytes
21 - 23
-
recombinant enzyme, forward reaction
25.8
-
purified recombinant enzyme, substrate guanine
27
-
purified recombinant enzyme, substrate hypoxanthine, pH 8.0
46
-
purified recombinant enzyme, substrate guanine, pH 8.0
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
8.8
assay at
7.4
-
assay at
7.8
-
assay at
additional information
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22
assay at room temperature
28
assay at
30
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
HPRT is strongly associated with the plasma membrane of SW-620 cells
Manually annotated by BRENDA team
-
a neuroblastoma cell line
Manually annotated by BRENDA team
-
amelanotic human melanoma cell, hypoxanthine phosphoribosyltransferase-negative
Manually annotated by BRENDA team
-
myeloid leukemic cell line
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
HPRT is strongly associated with the plasma membrane of SW-620 cells
Manually annotated by BRENDA team
additional information
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
metabolism
the enzyme is important in the purine metabolism pathways. Analysis and comparison of plasma and red blood cell hypoxanthine and inosine monophosphate concentrations and enzyme activities from bottlenose dolphins (Tursiops truncatus) and humans, overview. Hypoxanthine and inosine monophosphate concentrations are higher in plasma from dolphins than humans. Red blood cell concentrations of hypoxanthine, adenosine diphosphate, ATP, and guanosine triphosphate are lower in dolphins than in humans. Adenosine monophosphate and nicotinamide adenine dinucleotide concentrations are higher in dolphins. HGPRT activity in red blood cells is higher in humans than in dolphins
physiological function
malfunction
physiological function
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
HPRT_HUMAN
218
0
24579
Swiss-Prot
other Location (Reliability: 1)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
25000
x * 25000, SDS-PAGE
100000
-
3 charge variant forms, native gradient gel electrophoresis
24000
-
4 * 24000, SDS-PAGE
26000
68000
-
gel filtration
81000 - 83000
-
sedimentation equilibrium centrifugation
85000
-
sedimentation equilibrium method
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
x * 25000, SDS-PAGE
dimer
residues 198-204 are involved in the largest dimer interface
monomer or dimer
the recombinant chimeric enzyme exists as a mixture of monomeric and dimeric protein in solution, but shifts to a tetramer on addition of phosphoribosyl diphosphate
tetramer
the recombinant chimeric enzyme exists as a mixture of monomeric and dimeric protein in solution, but shifts to a tetramer on addition of phosphoribosyl diphosphate
dimer
tetramer
trimer
-
3 * 26000, SDS-PAGE
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
no glycoprotein
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
enzyme in complex with 2-(phosphonoethoxy)ethyl guanine, 2-(phosphonoethoxy)ethyl hypoxanthine, and (R,S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine, hanging drop vapor diffusion method, mixing of equal volumes of well solution, containing 0.1 M citrate pH 5.5, 10% isopropyl alcohol and 29% PEG 4000, and protein inhibitor complex with 17 mg/ml prtoein, and 3.3 mM for 2-(phosphonoethoxy)ethyl guanine, 3.9 mM (R,S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]guanine, and 3.0 mM for 2-(phosphonoethoxy)ethyl hypoxanthine, X-ray diffraction structure determination and analysis at 2.6-2.78 A resolution
in complex with T-705-RMP, hanging drop vapor diffusion method, using 0.2 M NaCl, 1 M sodium/potassium tartrate, 0.1 M imidazole, pH 8.0
purified enzyme in complex with inhibitor [3-(guanine-9-yl)-2-((2-phosphonoethoxy)methyl)propoxy]methylphosphonic acid and ([3-(guanine-9-yl)-2-((2-phosphonoethoxy)-methyl)propoxy]methyl)phosphonic acid, hanging drop method, mixing of 0.001 ml of 11.1 mg/ml protein in 0.1 M Tris-HCl, 0.01 M MgCl2, 1 mM DTT, and 0.3 mM 5-phospho-alpha-D-ribose 1-diphosphate, pH 7.4, and 4.8 mM inhibitor, with 0.001 ml of reservoir solution containing 20% PEG 3350, 0.2 M sodium bromide, 0.1 M Bis-Tris propane, pH 7.5, at 18°C, X-ray diffraction structure determination and analysis at 2.0 A resolution, molecular replacement and modeling
recombinant chimeric mutant enzyme complex with the product GMP, 12 mg/ml protein and 5 mM GMP in 0.1 M Tris, pH 8.0, and 2.0 M ammonium sulfate, 2-5 days, X-ray diffraction structure determination and analysis at 2.8 A resolution, modeling
spectral analysis of the crystal structure of the HGPRT/immucillin-G 5'-phosphate/diphosphate complex
ultraviolet resonance Raman spectroscopy study on the complexes of enzyme with products IMP, GMP, and XMP, both in Homo sapiens and Plasmodium falciparum, in resonance with the purine nucleobase electronic absorption. Human hypoxanthine guanine phosphoribosyltransferase catalyzes the phosphoribosylation of guanine and hypoxanthine, while the Plasmodium falciparum enzyme acts on xanthine as well. Spectra of bound nucleotides show that the enzyme distorts the structure of the nucleotides. The distorted structure resembles that of the deprotonated nucleotide. The two proteins assemble similar active sites for their common substrates. While the human enzyme does not bind XMP, Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferase perturbs the pKa of bound XMP
purified recombinant mutant C22A/C105A/C205A enzyme 1. free or 2. in complex with inactive purine base analogue 7-hydroxy [4,3d] pyrazolo pyrimidine and 5-phospho-alpha-D-ribose 1-diphosphate, or 3. complexed with IMP or GMP, or 4. complexed with transition state analogue immuncillinHP-Mg2+-diphosphate, hanging drop vapour diffusion method, 18 mg/ml protein in 0.05 M Tris-HCl, pH 7.4, 1 mM MgCl2, 1 mM DTT, mixing of 0.002 ml of both protein and reservoir solution, the latter containing 0.2 M ammonium acetate, 0.1 m sodium acetate, pH 4.6, 30% w/v PEG 4000, 17°C, 2-7 days, cryoprotection by 30% glycerol in reservoir solution, X-ray diffraction structure determination and analysis at 1.9 A resolution
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
C22A/C105A/C205A
site-directed mutagenesis, the exchanges stabilize the enzyme protein, but kinetic and structural properties of the mutant enzyme are identical to wild-type human HGPRT
F199C
a naturally occuring mutation T596G, leads to 8% residual HPRT activity and causes juvenile-onset, severe gouty arthritis, nephrolithiasis, and mild neurologic symptoms. Adenine phosphoribosyltransferase, APRT, EC 2.4.2.7, in erythrocytes from subjects with HPRT deficiency is typically increased about 2–3fold compared with controls. Modeling of the mutated protein for prediction of the mechanisms of partial enzymatic activity
F36A
site-directed mutagenesis, unaltered substrate specificity compared to the wild-type enzyme
F36E
site-directed mutagenesis, unaltered substrate specificity compared to the wild-type enzyme
F36G
site-directed mutagenesis, inactive mutant
F36K
site-directed mutagenesis, unaltered substrate specificity compared to the wild-type enzyme
F36W
site-directed mutagenesis, unaltered substrate specificity compared to the wild-type enzyme
A192V
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
A64P
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
C105A
-
prepared via splicing by overlap extension, reduced oxidation ofthe enzyme during storage
C205A
-
prepared via splicing by overlap extension, reduced oxidation ofthe enzyme during storage
C22A
-
prepared via splicing by overlap extension, reduced oxidation ofthe enzyme during storage
C22A/C105A/C205A
-
site-directed mutagenesis, kinetic and physical properties are similar to the wild-type enzyme, but the mutant enzyme is more resistant to oxidation
C23F
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
D185G
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
D31E
-
identification of another genetic variation within the gout-affected population in Taiwan with mutation on exon 2 with T to G transition at cDNA base 93 resulting in a change from aspartic acid to glutamic acid at position 31
D44V
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
E196A
-
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
E196D
-
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
E196Q
-
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
E196R
-
site-directed mutagenesis, the mutant shows increased activity compared to the wild-type enzyme
E196V
-
a naturally occuring mutation that leads to the Lesch-Nyhan syndrome
G140D
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
G70R
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
H204X
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
H60R
-
naturally occuring mutation of HPRT1 gene, causes no altered phenotype compared to the wild-type enzyme
I137T
-
DNA sequence determination and identification of the naturally occurring point mutation in the conserved 5-phosphoribosyl-1-diphosphate binding motif, causing a variant of Lesch-Nyhan syndrome, the mutation affects the affinity of the enzyme for 5-phosphoribosyl-1-diphosphate through structural alterations
I9S
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
K159E
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
K68A
-
conformational changes, shifted catalytic loop closer to the active site
L147F
-
natural occuring point mutation leading to enzyme deficiency, which is not correlated with a physiological syndrome
L147P
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
L65P
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
L68P
-
naturally occuring mutation in an Argentine individual, the patient shows the LND phenotype, determination of the altered urine purine alkaloid metabolite contents
L68R
-
naturally occuring mutation in an Argentine individual, the patient shows the LND phenotype, determination of the altered urine purine alkaloid metabolite contents
L78Q
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
M54L
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
P24R
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
P25T
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
Q144X
-
naturally occuring nonsense mutation of HPRT1 gene, exchange of 430C-T, causes the Lesch-Nyhan syndrome
R48H
-
naturally occuring mutation in an Argentine individual, the patient shows the HRND phenotype, determination of the altered urine purine alkaloid metabolite contents
R51X
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
S162R
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
T124P
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
T139P
-
naturally occuring mutation of HPRT1 gene, causes the Lesch-Nyhan syndrome
V158G
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
V188A
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
Y195C
Y195S
-
naturally occuring mutation in an Argentine individual, the patient shows the HRND phenotype, determination of the altered urine purine alkaloid metabolite contents
Y72C
-
naturally occuring mutation of HPRT1 gene, causes HPRT-related hyperuricemia
additional information
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
60
3 h, wild-type and mutant F36L, over 80% remaining activity
70
0.5 h, wild-type and mutant F36L, over 80% remaining activity
60
-
mutant and wild-type enzyme, 8 min, stable
85
-
if first incubated in 1 mM 5-phospho-alpha-D-ribose 1-diphosphate, remarkably stable
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
glycerol or sucrose or dimethylsulfoxide stabilizes the purified enzyme at -70°C
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-80°C, mutant and wild-type enzyme, stable up to 3 years
-
0°C, 10 mM phosphate, pH 7.1, 1 mM DTT, 10 mM Mg2+, 2 h, no loss of activity
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant chimeric mutant enzyme from Escherichia coli strain Su609 by anion exchange chromatography
recombinant wild-type and mutants F36L, F36G, F36K from Escherichia coli
2 methods
-
3 isoenzymes
-
from erythrocytes and from brain
-
recombinant enzyme
-
recombinant from Escherichia coli
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expression in Escherichia coli
expression of wild-type and mutant enzymes in Escherichia coli, functional complementation study
gene hprt, sequencing of wild-type and mutant enzymes
gene HPRT1, construction of expression vectors for recombinant expression of HPRT1, recombinant expression of GFP-tagged enzyme in HEK-293 cells on the outside of the plasma membrane, connected via the glycosyl-phosphatidylinositol, GPI, anchor on the cell surface, fluorescence analysis, method, overview
overexpression of the chimeric mutant enzyme in Escherichia coli strain Su609
expressed in Escherichia coli strain BL21(DE3)
-
expressed in MN-9D cells
-
expression of wild-type and chimeric enzymes in enzyme-deficient Escherichia coli strain, complementation study
-
functional expression of the HPRT enzyme from a minigene encoding human HPRT driven by the chicken beta-actin promoter in enzyme-deficient MN9D cell lines, which restores HPRT activity and reverses the engrailed transcription factor, En1 and En2, overexpression of the mutant
-
gene HGPRT, expression in Escherichia coli strain BL21(DE3)
-
gene HPRT, determination of the mutagenic potential of succinyl-acetone by determining the frequencies of somatic mutations in the HPRT reporter gene, overview
-
gene HPRT, DNA and amino acid sequence determination
-
gene HPRT, DNA sequence determination, expression analysis under different radiation conditions, overview
-
gene HPRT1
-
HPRT mutations, TCR gene rearrangements, and HTLV-1 integration sites define in vivo T-cell clonal lineages, overview, establishing of HPRT mutant mass cultures
-
overexpression in Escherichia coli
-
wild-type and mutant enzymes from lymphocytes treated or not treated with myosmine
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
mutational HPRT deficiency influences early developmental processes controlling the dopaminergic phenotype, and causes Lesch-Nyhan disease pathogenesis, microarray analysis of HPRT-deficient MN9D cells, phenotype, e.g. with increases in the mRNAs for engrailed 1 and 2, En1 and En2, transcription factors, overview. Restoration of HPRT reverses engrailed overexpression in MN9D cells
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
there is other evidence of salvage enzymes serving as diagnostic and prognostic biomarkers to diagnose and monitor cancer development in patient. Evaluation of enzymes, including HPRT, APRT, and DCK, as potential biomarkers for colorectal cancer (CRC). Colorectal cancer cell lines SW-480, SW-620, and HT-29 have statistically significant HPRT expression on the surface of the cells, while Colo-205 cells show no significant increase in the surface presence of HPRT. Analysis within malignant colon samples confirms the variable nature of HPRT surface localization within patients
analysis
-
the branched bi-enzyme system with xanthine oxidase is an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine, overview
medicine
molecular biology
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Smithers, G.W.; O'Sullivan, W.J.
Hypoxanthine phosphoribosyltransferase from human brain: purification and partial characterization
Biochem. Med.
32
106-121
1984
Homo sapiens
Manually annotated by BRENDA team
Olsen, A.S.; Milman, G.
Hypoxanthine phosphoribosyltransferase from Chinese hamster brain and human erythrocytes
Methods Enzymol.
51
543-549
1978
Cricetulus griseus, Homo sapiens
Manually annotated by BRENDA team
Gutensohn, W.; Huber, M.; Jahn, H.
Facilitated purification of hypoxanthine phosphoribosyltransferase
Hoppe-Seyler's Z. Physiol. Chem.
357
1379-1385
1976
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Arnold, W.J.; Kelley, W.N.
Human hypoxanthine-guanine phosphoribosyltransferase. Purification and subunit structure
J. Biol. Chem.
246
7398-7404
1971
Homo sapiens
Manually annotated by BRENDA team
Olsen, A.S.; Milman, G.
Human hypoxanthine phosphoribosyltransferase. Purification and properties
Biochemistry
16
2501-2505
1977
Homo sapiens
Manually annotated by BRENDA team
Muench, H.; Yoshida, A.
Purification and characterization of human hypoxanthine/guanine phosphoribosyltransferase
Eur. J. Biochem.
76
107-112
1977
Homo sapiens
Manually annotated by BRENDA team
Xu, Y.; Eads, J.; Sacchettini, J.C.; Grubmeyer, C.
Kinetic mechanism of human hypoxanthine-guanine phosphoribosyltransferase: rapid phosphoribosyl transfer chemistry
Biochemistry
36
3700-3712
1997
Homo sapiens
Manually annotated by BRENDA team
Keough, D.T.; Ng, A.L.; Winzor, D.J.; Emmerson, B.T.; de Jersey, J.
Purification and characterization of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase and comparison with the human enzyme
Mol. Biochem. Parasitol.
98
29-41
1999
Homo sapiens, Plasmodium falciparum
Manually annotated by BRENDA team
Sujay Subbayya, I.N.; Sukumaran, S.; Shivashankar, K.; Balaram, H.
Unusual substrate specificity of a chimeric hypoxanthine-guanine phosphoribosyltransferase containing segments from the Plasmodium falciparum and human enzymes
Biochem. Biophys. Res. Commun.
272
596-602
2000
Homo sapiens, Plasmodium falciparum
Manually annotated by BRENDA team
Wang, F.; Shi, W.; Nieves, E.; Angeletti, R.H.; Schramm, V.L.; Grubmeyer, C.
A transition-state analogue reduces protein dynamics in hypoxanthine-guanine phosphoribosyltransferase
Biochemistry
40
8043-8054
2001
Homo sapiens
Manually annotated by BRENDA team
Lee, C.C.; Medrano, F.J.; Craig, S.P., 3rd; Eakin, A.E.
Investigation of the functional role of active site loop II in a hypoxanthine phosphoribosyltransferase
Biochim. Biophys. Acta
1537
63-70
2001
Homo sapiens, Trypanosoma cruzi
Manually annotated by BRENDA team
Micheli, V.; Gathof, B.S.; Rocchigiani, M.; Jacomelli, G.; Sestini, S.; Peruzzi, L.; Notarantonio, L.; Cerboni, B.; Hayek, G.; Pompucci, G.
Biochemical and molecular study of mentally retarded patient with partial deficiency of hypoxanthine-guanine phosphoribosyltransferase
Biochim. Biophys. Acta
1587
45-52
2002
Homo sapiens
Manually annotated by BRENDA team
Raman, J.; Sumathy, K.; Anand, R.P.; Balaram, H.
A non-active site mutation in human hypoxanthine guanine phosphoribosyltransferase expands substrate specificity
Arch. Biochem. Biophys.
427
116-122
2004
Plasmodium falciparum, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Keough, D.T.; Brereton, I.M.; de Jersey, J.; Guddat, L.W.
The crystal structure of free human hypoxanthine-guanine phosphoribosyltransferase reveals extensive conformational plasticity throughout the catalytic cycle
J. Mol. Biol.
351
170-181
2005
Homo sapiens
Manually annotated by BRENDA team
Zoref-Shani, E.; Bromberg, Y.; Hirsch, J.; Feinstein, S.; Frishberg, Y.; Sperling, O.
A novel point mutation (I137T) in the conserved 5-phosphoribosyl-1-pyrophosphate binding motif of hypoxanthine-guanine phosphoribosyltransferase (HPRTJerusalem) in a variant of Lesch-Nyhan syndrome
Mol. Genet. Metab.
78
158-161
2003
Homo sapiens
Manually annotated by BRENDA team
Zheng, K.C.; Yalowich, J.C.; Kagan, V.E.; Keohavong, P.
Increased mutant frequencies in the HPRT gene locus of leukemia HL-60 cells treated with succinylacetone
Cell Biol. Toxicol.
22
361-370
2006
Homo sapiens
Manually annotated by BRENDA team
Allegretta, M.; Ardell, S.K.; Sullivan, L.M.; Jacobson, S.; Mortreux, F.; Wattel, E.; Albertini, R.J.
HPRT mutations, TCR gene rearrangements, and HTLV-1 integration sites define in vivo T-cell clonal lineages
Environ. Mol. Mutagen.
45
326-337
2005
Homo sapiens
Manually annotated by BRENDA team
Kalra, S.; Paul, M.K.; Balaram, H.; Mukhopadhyay, A.K.
Application of HPLC to study the kinetics of a branched bi-enzyme system consisting of hypoxanthine-guanine phosphoribosyltransferase and xanthine oxidase - an important biochemical system to evaluate the efficiency of the anticancer drug 6-mercaptopurine
J. Chromatogr. B
850
7-14
2007
Homo sapiens
Manually annotated by BRENDA team
Wu, C.H.; Lai, H.M.; Yang, M.C.; Liaw, C.C.; Chang, S.J.; Ko, Y.C.; Chen, C.J.
Identification of a new single-nucleotide mutation on the hypoxanthine-guanine phosphoribosyltransferase gene from 983 cases with gout in Taiwan
J. Rheumatol.
34
794-797
2007
Homo sapiens
Manually annotated by BRENDA team
Larovere, L.E.; ONeill, J.P.; Randall, M.; Fairbanks, L.D.; Guelbert, N.; Czornyj, L.; de Kremer, R.D.
Hypoxanthine-guanine phosphoribosyltransferase deficiency: biochemical and molecular findings in six Argentine patients
Nucleosides Nucleotides Nucleic Acids
26
255-258
2007
Homo sapiens
Manually annotated by BRENDA team
Kumar, P.R.; Mohankumar, M.N.; Hamza, V.Z.; Jeevanram, R.K.
Dose-rate effect on the induction of HPRT mutants in human G0 lymphocytes exposed in vitro to gamma radiation
Radiat. Res.
165
43-50
2006
Homo sapiens
Manually annotated by BRENDA team
Ea, H.K.; Bardin, T.; Jinnah, H.A.; Aral, B.; Liote, F.; Ceballos-Picot, I.
Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase
Arthritis Rheum.
60
2201-2204
2009
Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Deng, H.; Callender, R.; Schramm, V.L.; Grubmeyer, C.
Pyrophosphate activation in hypoxanthine-guanine phosphoribosyltransferase with transition state analogue
Biochemistry
49
2705-2714
2010
Homo sapiens (P00492)
Manually annotated by BRENDA team
Havla, J.B.; Hill, C.E.; Abdel-Rahman, S.Z.; Richter, E.
Evaluation of the mutagenic effects of myosmine in human lymphocytes using the HPRT gene mutation assay
Food Chem. Toxicol.
47
237-241
2009
Homo sapiens
Manually annotated by BRENDA team
Ceballos-Picot, I.; Mockel, L.; Potier, M.C.; Dauphinot, L.; Shirley, T.L.; Torero-Ibad, R.; Fuchs, J.; Jinnah, H.A.
Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch-Nyhan disease pathogenesis
Hum. Mol. Genet.
18
2317-2327
2009
Homo sapiens
Manually annotated by BRENDA team
Keough, D.T.; Hockova, D.; Holy, A.; Naesens, L.M.; Skinner-Adams, T.S.; Jersey, J.; Guddat, L.W.
Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics
J. Med. Chem.
52
4391-4399
2009
Plasmodium falciparum, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Guibinga, G.H.; Hsu, S.; Friedmann, T.
Deficiency of the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) dysregulates neurogenesis
Mol. Ther.
18
54-62
2010
Homo sapiens
Manually annotated by BRENDA team
Yamada, Y.; Nomura, N.; Yamada, K.; Wakamatsu, N.; Kaneko, K.; Fujimori, S.
Molecular analysis of hypoxanthine guanine phosphoribosyltransferase (HPRT) deficiencies: novel mutations and the spectrum of Japanese mutations
Nucleosides Nucleotides Nucleic Acids
27
570-574
2008
Homo sapiens
Manually annotated by BRENDA team
Canyuk, B.; E-Wan, A.; Keawwijit, W.; Nualnoi, T.; Sirisatean, L.; Tansakul, P.; Tanthana, C.
The role for glutamic acid at position 196 in human hypoxanthine phosphoribosyltransferase (HPRT) as investigated using site-directed mutagenesis
Nucleosides Nucleotides Nucleic Acids
27
894-899
2008
Homo sapiens
Manually annotated by BRENDA team
Gayathri, P.; Sujay Subbayya, I.; Ashok, C.; Senthamizh Selvi, T.; Balaram, H.; Murthy, M.
Crystal structure of a chimera of human and Plasmodium falciparum hypoxanthine guanine phosphoribosyltransferases provides insights into oligomerization
Proteins
73
1010-1020
2008
Homo sapiens (P00492), Homo sapiens, Plasmodium falciparum (P20035), Plasmodium falciparum
Manually annotated by BRENDA team
Baranowska-Bosiacka, I.; Dziedziejko, V.; Safranow, K.; Gutowska, I.; Marchlewicz, M.; Dolegowska, B.; Rac, M.E.; Wiszniewska, B.; Chlubek, D.
Inhibition of erythrocyte phosphoribosyltransferases (APRT and HPRT) by Pb2+: a potential mechanism of lead toxicity
Toxicology
259
77-83
2009
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Gogia, S.; Balaram, H.; Puranik, M.
Hypoxanthine guanine phosphoribosyltransferase distorts the purine ring of nucleotide substrates and perturbs the pKa of bound xanthosine monophosphate
Biochemistry
50
4184-4193
2011
Plasmodium falciparum, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Garozzo, R.; Sortino, M.A.; Vancheri, C.; Condorelli, D.F.
Antiproliferative effects induced by guanine-based purines require hypoxanthine-guanine phosphoribosyltransferase activity
Biol. Chem.
391
1079-1089
2010
Homo sapiens
Manually annotated by BRENDA team
Seinen, M.; De Boer, N.; Smid, K.; Van Asseldonk, D.; Bouma, G.; Van Bodegraven, A.; Peters, G.
Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: Preliminary data of an ongoing series
Nucleosides Nucleotides Nucleic Acids
30
1085-1090
2011
Homo sapiens
Manually annotated by BRENDA team
Mastrangelo, L.; Kim, J.E.; Miyanohara, A.; Kang, T.H.; Friedmann, T.
Purinergic signaling in human pluripotent stem cells is regulated by the housekeeping gene encoding hypoxanthine guanine phosphoribosyltransferase
Proc. Natl. Acad. Sci. USA
109
3377-3382
2012
Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Clinch, K.; Crump, D.R.; Evans, G.B.; Hazleton, K.Z.; Mason, J.M.; Schramm, V.L.; Tyler, P.C.
Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase
Bioorg. Med. Chem.
21
5629-5646
2013
Homo sapiens, Plasmodium falciparum (P20035)
Manually annotated by BRENDA team
Karnawat, V.; Gogia, S.; Balaram, H.; Puranik, M.
Differential distortion of purine substrates by human and Plasmodium falciparum hypoxanthine-guanine phosphoribosyltransferase to catalyse the formation of mononucleotides
ChemPhysChem
16
2172-2181
2015
Homo sapiens (P00492), Homo sapiens, Plasmodium falciparum (P20035), Plasmodium falciparum
Manually annotated by BRENDA team
Naesens, L.; Guddat, L.W.; Keough, D.T.; van Kuilenburg, A.B.; Meijer, J.; Vande Voorde, J.; Balzarini, J.
Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)
Mol. Pharmacol.
84
615-629
2013
Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Keough, D.T.; Rejman, D.; Pohl, R.; Zbornikova, E.; Hockova, D.; Croll, T.; Edstein, M.D.; Birrell, G.W.; Chavchich, M.; Naesens, L.M.J.; Pierens, G.K.; Brereton, I.M.; Guddat, L.W.
Design of Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase inhibitors as potential antimalarial therapeutics
ACS Chem. Biol.
13
82-90
2018
Plasmodium falciparum (A0A1G4HBT9), Plasmodium falciparum (Q8IJS1), Plasmodium falciparum, Homo sapiens (P00492)
Manually annotated by BRENDA team
Lopez-Cruz, R.I.; Crocker, D.E.; Gaxiola-Robles, R.; Bernal, J.A.; Real-Valle, R.A.; Lugo-Lugo, O.; Zenteno-Savin, T.
Plasma hypoxanthine-guanine phosphoribosyl transferase activity in bottlenose dolphins contributes to avoiding accumulation of non-recyclable purines
Front. Physiol.
7
213
2016
Tursiops truncatus, Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Spacek, P.; Keough, D.T.; Chavchich, M.; Dracinsky, M.; Janeba, Z.; Naesens, L.; Edstein, M.D.; Guddat, L.W.; Hockova, D.
Synthesis and evaluation of asymmetric acyclic nucleoside bisphosphonates as inhibitors of Plasmodium falciparum and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferase
J. Med. Chem.
60
7539-7554
2017
Homo sapiens (P00492), Homo sapiens, Plasmodium falciparum (Q8IJS1), Plasmodium falciparum
Manually annotated by BRENDA team
Townsend, M.H.; Felsted, A.M.; Burrup, W.; Robison, R.A.; O'Neill, K.L.
Examination of hypoxanthine guanine phosphoribosyltransferase as a biomarker for colorectal cancer patients
Mol. Cell. Oncol.
5
e1481810
2018
Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team
Nguyen, K.V.; Naviaux, R.K.; Nyhan, W.L.
Lesch-Nyhan disease I. Construction of expression vectors for hypoxanthine-guanine phosphoribosyltransferase (HGprt) enzyme and amyloid precursor protein (APP)
Nucleosides Nucleotides Nucleic Acids
39
905-922
2020
Homo sapiens (P00492), Homo sapiens
Manually annotated by BRENDA team